An example of inclusion and exclusion criteria
| . | Inclusions . | Exclusions . |
|---|---|---|
| Participants | Aged older than 16 years | Diseases with disease-specific immunodeficiencies (eg, CLL, myeloma, HIV-associated lymphoma) |
| Lymphoma confirmed on biopsy (based on predefined classifications) | ||
| Intervention | G-CSF or GM-CSF at a dose of at least 1 μg/kg/d given as primary prophylaxis for nonmyeloablative neutropenia, given within 72 hours after chemotherapy | Sequential administration of G-CSF or GM-CSF |
| First- or second-line chemotherapy | Secondary prophylaxis | |
| Both groups to receive identical supportive care | Use during established neutropenia | |
| Stem cell transplantation | ||
| Types of studies | Randomized controlled studies comparing G-CSF or GM-CSF with placebo or no prophylaxis | Crossover studies, quasi-randomized studies (allocation by nonrandom methods, eg, DoB, name) or nonrandomized studies |
| Abstracts or unpublished work with sufficient information. | Abstracts or unpublished work with insufficient information | |
| Outcomes to be measured (requires at least 1 for inclusion) | Overall survival | |
| Freedom from treatment failure | ||
| Quality of life | ||
| Risk and duration of neutropenia | ||
| Risk and duration of febrile neutropenia | ||
| Infection | ||
| Mortality | ||
| Etc |
| . | Inclusions . | Exclusions . |
|---|---|---|
| Participants | Aged older than 16 years | Diseases with disease-specific immunodeficiencies (eg, CLL, myeloma, HIV-associated lymphoma) |
| Lymphoma confirmed on biopsy (based on predefined classifications) | ||
| Intervention | G-CSF or GM-CSF at a dose of at least 1 μg/kg/d given as primary prophylaxis for nonmyeloablative neutropenia, given within 72 hours after chemotherapy | Sequential administration of G-CSF or GM-CSF |
| First- or second-line chemotherapy | Secondary prophylaxis | |
| Both groups to receive identical supportive care | Use during established neutropenia | |
| Stem cell transplantation | ||
| Types of studies | Randomized controlled studies comparing G-CSF or GM-CSF with placebo or no prophylaxis | Crossover studies, quasi-randomized studies (allocation by nonrandom methods, eg, DoB, name) or nonrandomized studies |
| Abstracts or unpublished work with sufficient information. | Abstracts or unpublished work with insufficient information | |
| Outcomes to be measured (requires at least 1 for inclusion) | Overall survival | |
| Freedom from treatment failure | ||
| Quality of life | ||
| Risk and duration of neutropenia | ||
| Risk and duration of febrile neutropenia | ||
| Infection | ||
| Mortality | ||
| Etc |
An example of inclusion and exclusion criteria for studies to be included in a systematic review of colony-stimulating factor use for the prevention of adverse effects in the treatment of lymphoma.13
CLL indicates chronic lymphoblastic leukemia leukemia; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage; and DoB, date of birth.